Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Bonner Website

William M. Bonner, Ph.D.

Selected Publications

1)  Moroni M, Maeda D, Whitnall MH, Bonner WM, Redon CE.
Evaluation of the Gamma-H2AX Assay for Radiation Biodosimetry in a Swine Model.
Int J Mol Sci. 14: 14119-35, 2013.
2)  Dickey JS, Gonzalez Y, Aryal B, Mog S, Nakamura AJ, Redon CE, Baxa U, Rosen E, Cheng G, Zielonka J, Parekh P, Mason KP, Joseph J, Kalyanaraman B, Bonner W, Herman E, Shacter E, Rao VA.
Mito-Tempol and Dexrazoxane Exhibit Cardioprotective and Chemotherapeutic Effects through Specific Protein Oxidation and Autophagy in a Syngeneic Breast Tumor Preclinical Model.
PLoS ONE. 8: e70575, 2013.
3)  Weyemi U, Redon CE, Parekh PR, Dupuy C, Bonner WM.
NADPH Oxidases NOXs and DUOXs as Putative Targets for Cancer Therapy.
Anticancer Agents Med Chem. 13: 502-14, 2013.
4)  Talbert PB, Ahmad K, Almouzni G, Ausió J, Berger F, Bhalla PL, Bonner WM, Cande WZ, Chadwick BP, Chan SW, Cross GA, Cui L, Dimitrov SI, Doenecke D, Eirin-López JM, Gorovsky MA, Hake SB, Hamkalo BA, Holec S, Jacobsen SE, Kamieniarz K, Khochbin S, Ladurner AG, Landsman D, Latham JA, Loppin B, Malik HS, Marzluff WF, Pehrson JR, Postberg J, Schneider R, Singh MB, Smith MM, Thompson E, Torres-Padilla ME, Tremethick DJ, Turner BM, Waterborg JH, Wollmann H, Yelagandula R, Zhu B, Henikoff S.
A unified phylogeny-based nomenclature for histone variants.
Epigenetics Chromatin. 5: 7, 2012.
5)  Dickey JS, Baird BJ, Redon CE, Avdoshina V, Palchik G, Wu J, Kondratyev A, Bonner WM, Martin OA.
Susceptibility to bystander DNA damage is influenced by replication and transcriptional activity.
Nucleic Acids Res. 40: 10274-86, 2012.
6)  Ivashkevich A, Redon CE, Nakamura AJ, Martin RF, Martin OA.
Use of the ?-H2AX assay to monitor DNA damage and repair in translational cancer research.
Cancer Lett. 327: 123-33, 2012.
7)  Redon CE, Weyemi U, Parekh PR, Huang D, Burrell AS, Bonner WM.
gamma-H2AX and other histone post-translational modifications in the clinic.
Biochim Biophys Acta. [Epub ahead of print], 2012.
8)  Kinders RJ, Hollingshead M, Lawrence S, Ji J, Tabb B, Bonner WM, Pommier Y, Rubinstein L, Evrard YA, Parchment RE, Tomaszewski J, Doroshow JH.
Development of a validated immunofluorescence assay for gammaH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.
Clin. Cancer Res. 16: 5447-57, 2010.
9)  Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH, Pommier Y.
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.
Clin. Cancer Res. 16: 4532-42, 2010.
10)  Nakamura AJ, Rao VA, Pommier Y, Bonner WM.
The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks.
Cell Cycle. 9: 389-97, 2010.
Click Here to View Expanded Bibliography.

This page was last updated on 9/16/2013.